ALBO Insider Trading Activity and SEC Form 4 Filings
ALBO insider trading summary
No open-market insider purchases or sales of Albireo Pharma, Inc. (ALBO) have been reported on SEC Form 4 in the past 12 months.
Latest ALBO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 23, 2023 | Jan Mattsson | Chief Scientific Officer | Sell | $9K (197 @ $43.80) |
| Jan 23, 2023 | Pamela Stephenson | Chief Commercial Officer | Sell | $4K (102 @ $43.80) |
| Jan 23, 2023 | Simon N.R. Harford | CFO and Treasurer | Sell | $4K (102 @ $43.80) |
| Jan 23, 2023 | Jason Duncan | Chief Legal Officer and GC | Sell | $10K (228 @ $43.80) |
| Jan 23, 2023 | Ronald Harold Wilfred Cooper | President and CEO | Sell | $46K (1,057 @ $43.80) |
| Jan 23, 2023 | Martha J. Carter | Chief Regulatory Officer | Sell | $5K (120 @ $43.80) |
| Jan 23, 2023 | Michelle Graham | Chief Human Resources Officer | Sell | $4K (102 @ $43.80) |
| Jan 19, 2023 | Simon N.R. Harford | CFO and Treasurer | Sell | $78K (1,776 @ $43.80) |
| Jan 19, 2023 | Michelle Graham | Chief Human Resources Officer | Sell | $78K (1,774 @ $43.90) |
| Jan 19, 2023 | Pamela Stephenson | Chief Commercial Officer | Sell | $78K (1,774 @ $43.90) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.